Sensorion, a biotech company focused on developing novel treatments for hearing loss disorders, announced today that it has raised €50.5 million from a group of investors, including existing shareholders Redmile Group, Invus and Sofinnova Partners, and new US healthcare specialists funds. The company will issue 88.6 million new shares at €0.57 each.

The funds will be used to support Sensorion’s gene therapy programs, which are based on a collaboration with the Institut Pasteur. The company’s lead program, SENS-501, has received approval to start a Phase 1/2 clinical trial, Audiogene, in some European countries, with France as the first country. The company is also working on its second gene therapy program, GJB2-GT, which aims to submit clinical trial applications in the first half of 2025.

Nawal Ouzren, CEO of Sensorion, said: “This strengthened shareholder base reinforces Sensorion’s ambition to advance its pipeline of innovative therapies intended to improve the quality of life of patients suffering from hearing disorders.”

Khalil Barrage, ad interim Chair of Sensorion, said: “Their arrival in Sensorion’s capital not only strengthens our financial foundation but also propels us forward on our path to innovation and scientific breakthrough for patients suffering from hearing disorders.”

AQEMIA raises €60M to boost its AI-powered drug discovery platform and pipeline